CALR and essential thrombocythemia: Similarly, in a study involving CALR-mutated ET patients, pegylated IFNα reduced the CALR variant allele fraction from 41% to 26%, whereas two patients achieved a complete molecular remission response for more than a year after the termination of IFN treatment, suggesting long-standing treatment-free hematological responses in CALR mutated patients [176].